ATE295376T1 - Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung - Google Patents

Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung

Info

Publication number
ATE295376T1
ATE295376T1 AT99941314T AT99941314T ATE295376T1 AT E295376 T1 ATE295376 T1 AT E295376T1 AT 99941314 T AT99941314 T AT 99941314T AT 99941314 T AT99941314 T AT 99941314T AT E295376 T1 ATE295376 T1 AT E295376T1
Authority
AT
Austria
Prior art keywords
sub
receptor
csf
cytokine
binding
Prior art date
Application number
AT99941314T
Other languages
English (en)
Inventor
Angel Lopez
Andrea Richard D
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Application granted granted Critical
Publication of ATE295376T1 publication Critical patent/ATE295376T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99941314T 1998-08-13 1999-08-13 Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung ATE295376T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP5251A AUPP525198A0 (en) 1998-08-13 1998-08-13 Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
PCT/AU1999/000659 WO2000009561A1 (en) 1998-08-13 1999-08-13 Monoclonal antibody inhibitor of gm-csf, il-3, il-5 and other cytokines, and uses thereof

Publications (1)

Publication Number Publication Date
ATE295376T1 true ATE295376T1 (de) 2005-05-15

Family

ID=3809483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99941314T ATE295376T1 (de) 1998-08-13 1999-08-13 Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung

Country Status (6)

Country Link
US (2) US6720155B1 (de)
EP (1) EP1105426B1 (de)
AT (1) ATE295376T1 (de)
AU (1) AUPP525198A0 (de)
DE (1) DE69925279T2 (de)
WO (1) WO2000009561A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
AU773029B2 (en) 1999-02-08 2004-05-13 Medvet Science Pty. Ltd. Cytokine-binding domain
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US8062637B2 (en) 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
WO2009006688A1 (en) * 2007-07-11 2009-01-15 Medvet Science Pty Ltd Regulating il-4 and il- 13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
GB0723179D0 (en) * 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
EP2193790A1 (de) * 2008-12-04 2010-06-09 Klinikum der Universität Regensburg IL-3-Inhibitoren zur Verwendung bei der Behandlung von rheumatoider Arthritis im Frühstadium
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20190112378A1 (en) * 2015-08-18 2019-04-18 University Of South Australia Novel cancer treatment involving modulation of il-3 activity
CN108368167B (zh) * 2015-11-27 2023-09-05 杰特有限公司 Cd131结合蛋白及其应用
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen
US20250188173A1 (en) * 2022-03-16 2025-06-12 CSL Innovation Pty Ltd Method of Treating an Eosinophil-Associated Disease
WO2024033522A1 (en) 2022-08-11 2024-02-15 Universitätsklinikum Regensburg Antibodies targeting il3
WO2024081996A1 (en) * 2022-10-20 2024-04-25 CSL Innovation Pty Ltd Method of treating severe asthma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
AU706462B2 (en) * 1996-01-30 1999-06-17 Medvet Science Pty. Ltd. Cytokine antagonists and agonists

Also Published As

Publication number Publication date
DE69925279T2 (de) 2006-01-26
AUPP525198A0 (en) 1998-09-03
US6720155B1 (en) 2004-04-13
EP1105426B1 (de) 2005-05-11
US7427401B2 (en) 2008-09-23
WO2000009561A1 (en) 2000-02-24
DE69925279D1 (de) 2005-06-16
US20040265957A1 (en) 2004-12-30
EP1105426A1 (de) 2001-06-13
EP1105426A4 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
DE69925279D1 (de) Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung
EP2336187B8 (de) Zusammensetzungen und Verfahren von monoklonalen oder polyklonalen Antikörpern, die spezifisch für T-Zell Subpopulationen sind
DE69128253D1 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
IT1306704B1 (it) Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
ATE178097T1 (de) Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen
DE59813519D1 (de) Mutiertes ScFv-Fragment des OKT-3 Antikörpers
DE69230146D1 (de) Monoklonale antikörper gegen putative hcv-e2/ns1-proteine und verfahren zu ihrer verwendung
ATE279443T1 (de) A3c6e2, ein monoklonaler antikörper spezifisch für den humanen stammzellfaktor (scf)-rezeptor
EP2186884A3 (de) Monoklonale Antikörpergegen HCV Kernantigen
CY1107858T1 (el) Ccr5 αντισωματα pa14
CY1110144T1 (el) Αντισωματα για την ταυτοποιηση και/ή την απομονωση τουλαχιστον ενος κυτταρικου πληθυσμου ο οποιος επιλεγεται απο την ομαδα την περιλαμβανουσα αιμοποιητικα βλαστοκυτταρα, νευρικα βλαστοκυτταρα, νευρικα αρχεγονα κυτταρα, μεσεγχυματικα βλαστοκυτταρα και μεσεγχυματικα αρχεγονα κυτταρα
BRPI0510079A (pt) anticorpo isolado ou região de ligação de antìgeno do mesmo, célula de hibridoma, célula de transfectoma, anticorpo monoclonal ou região de ligação de antìgeno do mesmo, animal não humano transgênico, método para produzir um anticorpo ou região de ligação de antìgeno do mesmo, composição farmacêutica, uso do anticorpo ou região de ligação de antìgeno, polipeptìdeo isolado, imunoensaio, e, método para identificar um composto
EP0525005A4 (en) Method for inhibiting cell growth and compositions useful therefor
EP4527465A3 (de) Anti-glypican-3-antikörper
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
DE69933565D1 (de) Serinprotease-spzifischer moniklonaler antikörper und seine verwendung
ATE544783T1 (de) Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
CA2480717A1 (en) Method for producing monoclonal antibodies
DK0840620T3 (da) IL-8-antagonister til behandling af astma
DE3576359D1 (de) Verfahren zur herstellung von tumorspezifische monoklonale antikoerper produzierenden hybridomazellen.
WO2004025293A3 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
Shinjo et al. Monoclonal anti-λ5 antibody FS1 identifies a 130 kDa protein associated with λ5 and Vpre-B on the surface of early pre-B cell lines
WO2023178201A3 (en) Methods of identifying anti-lag-3 agents
EP0889054A3 (de) Antikörper 67D2 gegen CD164

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties